Who is sponsoring NCT03003546?

NCT03003546 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03003546?

Interventions in NCT03003546: Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study.

What condition does NCT03003546 study?

NCT03003546 studies Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma.

Is NCT03003546 still recruiting?

NCT03003546 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT03003546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Completed Phase 1 Last updated 15 June 2023

What this trial tests

Phase 1 trial testing Laboratory Biomarker Analysis in Recurrent Aggressive Non-Hodgkin Lymphoma in 9 participants. Completed in 16 May 2023.

Timeline

25 April 2019

Primary endpoint
16 May 2023

16 May 2023

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	25 April 2019
Primary completion	16 May 2023
Estimated completion	16 May 2023
Sites	1 location across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 — full drug profile →
Pharmacological Study — full drug profile →

Conditions studied

Recurrent Aggressive Non-Hodgkin Lymphoma — all drugs for Recurrent Aggressive Non-Hodgkin Lymphoma →
Recurrent B-Cell Non-Hodgkin Lymphoma — all drugs for Recurrent B-Cell Non-Hodgkin Lymphoma →
Recurrent Small Lymphocytic Lymphoma — all drugs for Recurrent Small Lymphocytic Lymphoma →
Refractory Aggressive Non-Hodgkin Lymphoma — all drugs for Refractory Aggressive Non-Hodgkin Lymphoma →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Recurrent Aggressive Non-Hodgkin Lymphoma or Recurrent B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating patients with B-cell non-Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Nab-paclitaxel/rituximab-coated nanoparticle AR160 is a combination of paclitaxel albumin-stabilized nanoparticle formulation and rituximab. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel albumin-stabilized nanoparticle formulation and rituximab may work better in treating patients with B-cell non-Hodgkin lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nanomaterials for cancer therapy: current progress and perspectives.
Cheng Z, Li M, Dey R, Chen Y. · · 2021 · cited 584× · PMID 34059100 · DOI 10.1186/s13045-021-01096-0
Biomedical nanomaterials for immunological applications: ongoing research and clinical trials.
Lenders V, Koutsoumpou X, Sargsian A, Manshian BB. · · 2020 · cited 59× · PMID 36132021 · DOI 10.1039/d0na00478b
TME-Related Biomimetic Strategies Against Cancer.
Peng C, Xu Y, Wu J, Wu D, et al · · 2024 · cited 57× · PMID 38192633 · DOI 10.2147/ijn.s441135
Nanopharmaceutics: Part II-Production Scales and Clinically Compliant Production Methods.
Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, et al · · 2020 · cited 41× · PMID 32143286 · DOI 10.3390/nano10030455
Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
Tracey SR, Smyth P, Barelle CJ, Scott CJ. · · 2021 · cited 13× · PMID 34709394 · DOI 10.1042/bst20210343
The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers.
Freitas LF, Ferreira AH, Thipe VC, Varca GHC, et al · · 2021 · cited 11× · PMID 34685018 · DOI 10.3390/nano11102579
Advances in nano-immunotherapy for hematological malignancies.
Xu J, Liu W, Fan F, Zhang B, et al · · 2024 · cited 10× · PMID 38796455 · DOI 10.1186/s40164-024-00525-3
Nanotechnology for immuno-oncology.
Grippin AJ, Lee D, Parkes EE, Jiang W, et al · · 2025 · cited 7× · PMID 40775548 · DOI 10.1038/s43018-025-01025-x

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03003546 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03003546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing